3 results
Approved WMOCompleted
To evaluate the safety and effectiveness of Orsiro for the treatment of subjects with up to 2 de novo atherosclerotic coronary artery lesions.
Approved WMOCompleted
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Approved WMOCompleted
The primary objective of this study is to examine the direct influence of the grasp support system on (functional) performance and movement execution of the most-affected arm and hand. Secondary objectives are to examine the direct effect of the…